Drug
ARRY-334543 clinical trials
Also written Varlitinib, ASLAN001 and ARRY-334543.
- studies test it
- 18
- open now
- 0
- in phase 3
- 2
- first study started
- 2006
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
18 studies that test it; most in 2017 (5)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 12
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 13
ASLAN Pharmaceuticals (9) · Array Biopharma, now a wholly owned subsidiary of Pfizer (4) · National Cancer Centre, Singapore (2) · National University Hospital, Singapore (2) · Array BioPharma (1)
Often tested with
Tested in the same studies.
Capecitabine (3) · Cisplatin (1) · Gemcitabine (1) · CAPOX Regimen (1) · Modified FOLFOX6 Regimen (1) · Paclitaxel (1) · Carboplatin (1)
Studies
Open first, then newest update. How each study uses ARRY-334543 is read from its arms, and is right about nine times in ten.
Testing it · 18
- Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast CancerTerminatedPhase 2National Cancer Centre, SingaporeNCT07166367Written as ASLAN001
- Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)CompletedPhase 2/3ASLAN PharmaceuticalsNCT03130790Written as Varlitinib
- Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract CancerCompletedPhase 2/3ASLAN PharmaceuticalsNCT03093870Written as Varlitinib
- ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With LeucovorinStatus unknownPhase 1National Cancer Centre, SingaporeNCT02435927Written as ASLAN001+ CAPOX (Oxaliplatin, capecitabine)
- Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTCTerminatedPhase 1/2ASLAN PharmaceuticalsNCT02992340Written as Varlitinib
- Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract CancerCompletedPhase 2ASLAN PharmaceuticalsNCT03231176Written as Varlitinib
- A Study of ARRY-334543 in Patients With Advanced CancerCompletedPhase 1Array Biopharma, now a wholly owned subsidiary of PfizerNCT00278902Written as ARRY-334543, EGFR/ErbB2 inhibitor; oral
- A Study of ARRY-334543 in Patients With Advanced CancerCompletedPhase 1Array Biopharma, now a wholly owned subsidiary of PfizerNCT00637702Written as ARRY-334543, EGFR/ErbB2 inhibitor; oral
- A Study of ARRY-334543 and Docetaxel in Patients With Advanced CancerCompletedPhase 1Array Biopharma, now a wholly owned subsidiary of PfizerNCT00833326Written as ARRY-334543, EGFR/ErbB2 inhibitor; oral
- A Study of ARRY-334543 and Capecitabine in Patients With Advanced CancerCompletedPhase 1Array Biopharma, now a wholly owned subsidiary of PfizerNCT00710736Written as ARRY-334543, EGFR/ErbB2 inhibitor; oral
- Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-VarlitinibCompletedPhase 1ASLAN PharmaceuticalsNCT03368846Written as Varlitinib
- ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic TherapyCompletedPhase 2ASLAN PharmaceuticalsNCT02609958Written as Varlitinib
- Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract CancerWithdrawnPhase 2ASLAN PharmaceuticalsNCT03129074Written as Varlitinib
- Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)Status unknownPhase 1/2National University Hospital, SingaporeNCT03499626Written as ASLAN001
- Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior TrastuzumabCompletedPhase 2ASLAN PharmaceuticalsNCT02338245Written as ASLAN001
- Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast CancerStatus unknownPhase 1/2National University Hospital, SingaporeNCT02396108Written as Paclitaxel + Carboplatin + ASLAN001
- A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2CompletedPhase 2ASLAN PharmaceuticalsNCT01614522Written as ASLAN001
- A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic CancerCompletedPhase 1/2Array BioPharmaNCT00862524Written as ARRY-334543, EGFR/ErbB2 inhibitor; oral
Given in every arm · 2 — ARRY-334543 is usual care beside what is tested
- Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and CapecitabineCompletedPhase 1ASLAN PharmaceuticalsNCT02648425Written as ASLAN001
- A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid TumoursCompletedPhase 1ASLAN PharmaceuticalsNCT03082053Written as varlitinib